HKB99

HKB99 is an allosteric inhibitor of phosphoglycerate mutase 1 (PGAM1) . HKB99 induces apoptosis. HKB99 inhibits the formation of invasive pseudopodia and inhibits migration. HKB99 increases the oxidative stress, activates JNK/c-Jun and suppresses AKT and ERK. HKB99 can be used for the research of non-small-cell lung cancer (NSCLC) [1][2].

Product Specifications

CAS Number

[2414908-90-8]

UNSPSC

12352005

Target

Akt; Apoptosis; ERK; Phosphatase; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/hkb99.html

Purity

98.58

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C1C2=C(C=C(NS(C3=CC=C(N4CCC4)C=C3)(=O)=O)C(O)=C2O)C(C5=CC=CC=C51)=O

Molecular Formula

C23H18N2O6S

Molecular Weight

450.46

References & Citations

[1]Liang Q, et al. HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells. Acta Pharmacol Sin. 2021 Jan;42 (1) :115-119.|[2]Huang K, et al. A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer. Cell Metab. 2019 Dec 3;30 (6) :1107-1119.e8.